Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
During the COVID-19 pandemic, the net number of retail independent pharmacies nationwide increased.
JC Scott sits down with Ross Margulies, a Partner with special expertise in Medicare and Medicaid law at Foley Hoag LLP. JC and Ross discuss the antitrust litigations that have shaped the drug supply chain.
The Food and Drug Administration (FDA) has approved Aduhelm to treat Alzheimer’s disease. Learn the perspective of America’s pharmacy benefit managers, PBMs, which are positioned squarely at the intersection of access and affordability for patients.
Medicare beneficiaries appreciate the Biden Administration’s decision to delay the prescription drug rebate rule.
Learn MoreMay 19, 2021
(Washington, D.C.) — Today, the Pharmaceutical Care Management Association (PCMA)...
Keep ReadingMay 18, 2021
(Washington, D.C.) — As the House Committee on Oversight and Reform...
Keep ReadingJune 21, 2021
An analysis of federal data showed Medicaid enrollment rose from 71.3 million to 80.5 million between February 2020 and January...
Keep ReadingJune 21, 2021
Roche Holding's Cobas SARS-CoV-2 nucleic acid test was granted Emergency Use Authorization by the FDA. The RT-PCR-based test will be...
Keep Reading
PCMA believes that organizational and employee success require a diverse, equitable, and inclusive workforce and a culture that embraces and encourages different perspectives. We recognize the inherent value in employing a workforce with a range of experiences and it is our commitment to embrace every person’s uniqueness and to provide a professional work environment where everyone is welcome and treated with dignity and respect.
PCMA has signed on to the CEO Action for Diversity & Inclusion™ pledge. Read more here.
